Novartis Leqvio Launch Lags As COVID-19 Hinders England Access Scheme
Swiss Giant Waiting For Moratorium To Be Lifted
The CEO and head of pharma at Novartis have both cautioned against expectations of a lucrative launch for Leqvio, saying that a completely new approach to treating cholesterol lowering with a vaccine-like approach of administration twice a year will take time to get established in healthcare systems.
You may also be interested in...
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.
Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.
AstraZeneca and Ionis believe they have a potential best-in-class PCSK9 inhibitor, but the product will have to impress in forthcoming pivotal trials to catch up with Novartis’s Leqvio.